News Feature in 2014

As US legislatures and voters continue to wrestle with GM labeling, what is at stake? Jim Kling investigates.

As mass spectrometry makes inroads into pathogen identification in the clinical laboratory, deep sequencing—even nanopore sequencing—is waiting in the wings. Jeffrey L. Fox investigates.

Is the imminent release of the database of industry's 'gifts' to doctors cause for concern or celebration? Charles Schmidt investigates.

Neuron- and glia-like cells derived from induced pluripotent stem cells promise tractable, individualized human models of Alzheimer's, Parkinson's and amyotrophic lateral sclerosis. Ken Garber explores the considerable challenges of recreating such diseases in the laboratory.

The holy grail of printed human organs remains a long way off, but commercial efforts to print simple structures and tissues are forging ahead. Gunjan Sinha reports.

Despite the complexity of drought tolerance, researchers are making progress in the search for crops that can produce seed with limited water. Emily Waltz reports.

What is the secret sauce for a successful biotech company drug launch in 2014? Melanie Senior investigates.

Ease of use, economy and speed of targeting DNA has propelled the CRISPR-Cas system into the spotlight. Now, despite numerous gaps in our knowledge, commercial entities are looking for a piece of the action. Monya Baker reports.

Despite an overall dip in FDA approvals of new chemical and biologic entities, 2013 wasn't a bad year for innovator drugs. Jim Kling reports.

A growing market for therapeutic drugs to treat pets is fostering a startup boom. Gunjan Sinha reports.